Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis
Sebastian Wolf, Frank G Holz, Edoardo Midena, Eric H Souied, George Lambrou, Tobias Machewitz, Helmut Allmeier, Paul Mitchell, ARIES Study Investigators, Sebastian Wolf, Frank G Holz, Edoardo Midena, Eric H Souied, George Lambrou, Tobias Machewitz, Helmut Allmeier, Paul Mitchell, ARIES Study Investigators
Abstract
Introduction: The aim of this post hoc analysis of the ARIES study is to explore the requirement for intravitreal aflibercept (IVT-AFL) treatment intervals of < 8 weeks (w) in patients with neovascular age-related macular degeneration (nAMD), and to assess vision and anatomic outcomes in such patients who require more intensive treatment.
Methods: ARIES was a multicenter, randomized, phase 3b/4 study that investigated the efficacy of two IVT-AFL proactive, individualized, treat-and-extend regimens over 2 years in treatment-naïve patients with nAMD. Patients were determined as injection-intensive if the study investigator identified that a treatment interval of < 8 w was needed and if they had ≥ 1 interval of < 8 w after three initial monthly doses. Treatment intervals could be extended subsequently if extension criteria were met. This is a post hoc analysis of patients enrolled in ARIES and statistical analysis is descriptive.
Results: Of 269 patients in the combined treatment arms, 23.0% (n = 62) were injection-intensive (Year 1: 13.8% [n = 37]; Year 2: 9.3% [n = 25]). Time from IVT-AFL initiation to injection-intensive determination varied (range, 16-100 w; median: 43.2 w). Mean treatment interval was 8.4 w before and 6.1 w after injection-intensive determination. Overall, 59.7% achieved treatment intervals of ≥ 8 w following injection-intensive determination. Vision improvements from baseline to Week 104 were smaller for injection-intensive patients than non-injection-intensive patients (mean [SD] best-corrected visual acuity change: + 2.3 [15.6] vs. + 5.9 [12.3] letters). Anatomic outcomes were similar between injection-intensive and non-injection-intensive patients (central retinal thickness change from baseline to Week 104: - 160 [154] vs. - 167 [136] µm).
Conclusions: In ARIES, 23% of treatment-naïve patients with nAMD experienced at least one treatment interval of < 8 w. Injection-intensive patients showed improved vision and anatomic outcomes. For most, treatment intervals could be extended to ≥ 8 w following injection-intensive determination.
Clinicaltrials: gov Identifier: NCT02581891.
Keywords: Injection-intensive; Intravitreal aflibercept; Neovascular age-related macular degeneration; Treat-and-extend; Treatment intervals; Treatment outcomes.
© 2022. The Author(s).
Figures
References
- Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014;158:532–536. doi: 10.1016/j.ajo.2014.05.025.
- Jaffe GJ, Kaiser PK, Thompson D, et al. Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology. 2016;123:1856–1864. doi: 10.1016/j.ophtha.2016.05.016.
- Lanzetta P, Loewenstein A, Vision Academy Steering Committee Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255:1259–1273. doi: 10.1007/s00417-017-3647-4.
- Mitchell P, Holz GF, Hykin P, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study. Retina. 2021;41:1911–1920. doi: 10.1097/IAE.0000000000003128.
- Ross AH, Downey L, Devonport H. Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. Eye (Lond) 2020;34:1825–1834. doi: 10.1038/s41433-019-0747-x.
- Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193–201. doi: 10.1016/j.ophtha.2013.08.011.
- Eylea [prescribing information]. In. Tarrytown, NY: Regeneron Pharmaceuticals, Inc. 2021.
- Aflibercept (Eylea) summary of product characteristics, Nov 2021. . Accessed June 2022.
- Ohji M, Takahashi K, Okada AA, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR. Adv Ther. 2020;37:1173–1187. doi: 10.1007/s12325-020-01236-x.
- Brown DM. Evaluation of 8 mg intravitreal aflibercept injection for neovascular age-related macular degeneration: results from the phase 2 CANDELA study. Association for Research in Vision and Ophthalmology (ARVO) 2022.
Source: PubMed